Wellgistics Health, Inc. announced significant Q2 2025 operational results on June 25, 2025. The company added 116 new pharmaceutical manufacturer partnerships during the quarter. This expansion reflects accelerating momentum in creating a modern drug ecosystem.
Over 12,400 new products (NDCs) were integrated into its national platform. Additionally, more than 275 pharmacies were added to its expanding tech-based drug ecosystem. This growth aims to connect manufacturers directly to pharmacies, providers, employers, and patients.
This operational expansion is driven by a fully integrated, AI-powered infrastructure designed to streamline fulfillment and reduce costs. The company continues to bypass legacy bottlenecks in the pharmaceutical supply chain. These results demonstrate Wellgistics' ongoing commitment to its growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.